WHO ICTRP trial
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in…
JPRN-UMIN000006427 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000006427 |
|---|---|
| Public title | Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer |
| Scientific title | Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer - Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer |
| Primary sponsor | Toho University Omori Medical Center |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | metastic and recurrance breast cancer |
| Interventions | Nab-paclitaxel:125mg/m2 intravenously administred on day 1,8 every 3 weeks Gemcitabine:1000mg/m2 intravenously administred on day 1,8 every 3 weeks |
| Registration date | Sep 28, 2011 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: